Yun Sun-Mi, Kim Seok-Ho, Kim Eun-Hee
College of Pharmacy and Institute of Pharmaceutical Sciences, CHA University, Seongnam, South Korea.
Front Pharmacol. 2019 Feb 27;10:162. doi: 10.3389/fphar.2019.00162. eCollection 2019.
Inflammatory bowel disease is known as the most chronic inflammatory disorder in colon, which subsequently progresses to intestinal obstruction and fistula formation. Many studies to date for the treatment of IBD have been focused on inflammation. However, most of the anti-inflammatory agents do not have anti-fibrotic effects and could not relieve intestinal stricture in IBD patients. Because preventing or reversing intestinal fibrosis in IBD is a major therapeutic target, we analyzed the papers focusing on TGF-β signaling in intestinal fibrosis. TGF-β is a good candidate to treat the intestinal fibrosis in IBD which involves TGF-β signaling pathway, EMT, EndMT, ECM, and other regulators. Understanding the mechanism involved in TGF-β signaling will contribute to the treatment and diagnosis of intestinal fibrosis occurring in IBD as well as the understanding of the molecular mechanisms underlying the pathogenesis.
炎症性肠病是结肠中最常见的慢性炎症性疾病，随后会发展为肠梗阻和瘘管形成。迄今为止，许多治疗炎症性肠病的研究都集中在炎症方面。然而，大多数抗炎药物没有抗纤维化作用，无法缓解炎症性肠病患者的肠道狭窄。由于预防或逆转炎症性肠病中的肠道纤维化是一个主要的治疗靶点，我们分析了关注肠道纤维化中转化生长因子-β（TGF-β）信号传导的论文。TGF-β是治疗炎症性肠病中肠道纤维化的一个很好的候选药物，其涉及TGF-β信号通路、上皮-间质转化（EMT）、内皮-间质转化（EndMT）、细胞外基质（ECM）和其他调节因子。了解TGF-β信号传导所涉及的机制将有助于炎症性肠病中肠道纤维化的治疗和诊断，以及对发病机制背后分子机制的理解。
